MacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX

Core Viewpoint - MacroGenics, Inc. is facing a class action lawsuit due to alleged material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine, leading to a significant stock decline of 77.4% [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from March 7, 2024, to May 9, 2024 [2]. - The stock price of MGNX dropped by $11.36 per share following the revelation that the drug was more dangerous than previously claimed [2]. - Shareholders are encouraged to register for the class action by September 24, 2024, to potentially become lead plaintiffs [3]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].